


NIH NATIONAL CANCER INSTITUTE

BUDGET FACT BOOK

FOR FISCAL YEAR 2024



U.S. Department of Health & Human Services
National Institutes of Health

TABLE OF CONTENTS

3 NCI BUDGET FACT BOOK

- 3 Fiscal Year 2024 Highlights
- 4 Where to Find Information from Previous Fact Books

6 NCI BUDGET SUMMARY DATA

- 6 Most Recent Reported Fiscal Year Budget
- 7 Funding Allocated to Major NCI Program Areas
- 8 Extramural Funding
- 10 Obligations by Budget Mechanism and Division
- 28 NIH Management Fund, Service and Supply Fund (SSF), and GSA Rent
- 31 Special Sources of Funds
- 36 Funding for Research Areas

39 NCI EXTRAMURAL PROGRAMS

- 39 Research Project Grants (RPGs)
- 49 Grants to NCI-Designated Cancer Centers
- 56 Specialized Programs of Research Excellence (SPOREs)
- 59 Dr. Ruth L. Kirschstein National Research Service Awards (NRSA)
- 60 Research Career Awards “K” Program
- 62 Grant and Contract Awards

68 NCI HISTORICAL TRENDS

- 68 NCI Professional Judgment Budget, President’s Budget and Appropriations
- 76 NCI Funding Trends
- 79 Extramural vs Intramural and RMS Funding
- 82 Comparison of Dollars, Positions, and Space
- 83 NCI Personnel
- 84 NCI and NIH AIDS Funding History

85 CANCER MOONSHOTSM – RECENT FISCAL YEAR FUNDING

- 86 Cancer MoonshotSM - Obligations by Budget Mechanism
- 89 Cancer MoonshotSM - Funding by Research Category

NCI Budget Fact Book

This report provides a summary of the distribution of the fiscal year 2024 budget among the various NCI research programs and funding mechanisms, funding policies influencing grant awards, as well as comparisons with prior year allocations.

Fiscal Year 2024 Highlights

Funds available to the NCI totaled \$7.2 billion , post inter-departmental and intra-NIH transfers, including \$50 million for the Childhood Cancer Data Initiative and \$28 million for Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act. This reflects an increase of 1.7% and \$120 million from the previous fiscal year.

Fiscal year highlights include:

- The Childhood Cancer Data Initiative (CCDI) will facilitate a connected data infrastructure and integrate multiple data sources to make data work better for patients, clinicians, and researchers.
- The Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act, which was signed into law in June 2018, authorized funds for NCI to expand existing biorepositories for childhood cancer patients enrolled in NCI-sponsored clinical trials to collect and maintain relevant clinical, biological, and demographic information on children, adolescents, and young adults, and to continue to conduct and support pediatric cancer survivorship research.
- Of the total NCI budget obligated, 43.3% of the funds were allocated for Research Project Grants (RPGs).
- The total number of RPGs funded was 5,739 (including grants funded through the Small Business Innovation Research (SBIR) & Small Business Technology Transfer (STTR) programs).
- Approximately one-fourth of the RPGs awarded were new (“Type 1”) or competing renewal (“Type 2” or “Type 4”) awards.
- There was a total of 1,224 competing RPGs funded (excluding grants funded through SBIR & STTR).
- One-third of the total NCI budget supported ongoing, non-competing (“Type 5”) RPGs.
- The R01 grants were funded to the 10th percentile for Experienced and New Investigators and the Early-Stage Investigators were funded to the 17th percentile.
- R01 Early-Stage Investigators between the 1st and 10th percentiles were converted to R37 awards, giving them the opportunity to extend their research an additional 2 years.
- SBIR & STTR awards funded 199 grants totaling \$158.5 million.
- Intramural Research comprised 18.6% of the total NCI budget.


The dollar amounts displayed in the NCI Budget Fact Book represent direct appropriated funds only, unless otherwise denoted.

Where to Find Information from Previous Fact Books

Information provided in previous Fact Books can now be found online. For example, view NCI's Organization Chart on the NIH Office of Management Assessment website. Cancer statistics can be found on the NCI website, as well as more detailed NCI Organization information. A limited number of Fact Books from prior years are available as hardcopy publications through the NCI Publications Locator. Find PDFs of all the NCI Budget Fact Books, dating back to 1971.

The NCI Budget Fact Book data is organized into the following sections. If you have any questions, please contact the Office of Budget and Finance (OBF).

Budget At A Glance: Fiscal Year 2024



NCI BUDGET INCREASED BY **\$120 MILLION** (1.7%) FROM FISCAL YEAR 2023

43.3%


OF THE TOTAL NCI BUDGET ALLOCATED FOR RESEARCH PROJECT GRANTS (RPGs)

THE NATIONAL CANCER INSTITUTE (NCI) PROVIDES FUNDING AND SUPPORT FOR HEALTH-RELATED RESEARCH AND DEVELOPMENT THROUGH THE RPG (R01) GRANT MECHANISM.




R01 GRANTS FUNDED TO THE

10TH PERCENTILE



OF RPG AWARDS WERE NEW (TYPE 1) OR COMPETING RENEWAL (TYPE 2) AWARDS



OF THE TOTAL NCI BUDGET SUPPORTED ONGOING, NON-COMPETING (TYPE 5) RPGs

1,224

NCI-FUNDED COMPETING RPGs



TOTALING OVER \$158.5 MILLION FUNDED AS SMALL BUSINESS INNOVATION RESEARCH (SBIR) AND SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) AWARDS.

5,739

TOTAL NCI-FUNDED RPGs (INCLUDING SBIR)

NCI Budget Summary Data

This section of the NCI Budget Fact Book provides data about funds available to NCI and information on how NCI obligated its funding.

Most Recent Reported Fiscal Year Budget

In fiscal year 2024, Congress passed a consolidated appropriations act allocating \$7.224 billion to NCI. Following permissive transfers, NCI had \$7.259 billion available for obligation.

In addition to the appropriated amount for the fiscal year, NCI entered into inter- and intra-agency agreements with other federal agencies and NIH Institutes and Centers (ICs). These agreements often provide reimbursements for materials, supplies, equipment, work, or services to assist other agencies and ICs accomplish their missions.

FISCAL YEAR 2024 BUDGET

(Whole Dollars)

Actual Obligations Resulting From Appropriated Funds	FY 2024 Amount
FY 2024 Appropriation	\$7,224,159,000
Secretary's Transfer	\$0
Transfer to NIH Office of AIDS Research	-\$2,918,000
Lapse	-\$324,597
Actual Obligations Subtotal	\$7,220,916,403
Reimbursable Obligations	\$38,425,479
Total NCI Obligations	\$7,259,341,882

Funding Allocated to Major NCI Program Areas


Each fiscal year, NCI and other NIH Institutes and Centers report their obligations by mechanism. In addition to reporting by mechanism, reporting obligations by program structure is another way of showing how NCI obligates its funding each fiscal year.

For the purposes of reporting by program structure, NCI programs are categorized by budget activity. These budget activities include:

- **Research**, categorized by the following research thrusts: Childhood Cancer Data Initiative (CCDI), cancer causation, detection and diagnosis, treatment, and cancer biology
- **Resource Development**: cancer centers, research manpower development, and buildings and facilities
- **Cancer Prevention and Control**
- **Program Management and Support**

Program Structure

Fiscal Year 2024




cancer.gov

Extramural Funding

Overall, NCI obligations for its extramural program, including grants and contracts, totaled \$5.35 billion in fiscal year 2024.

- Obligations for grants totaled approximately 82.8% of extramural funding
- Obligations for contracts totaled approximately 17.2% of extramural funding



EXTRAMURAL FUNDS, FISCAL YEAR 2024

(Whole Dollars)

Mechanism	Amount	Percent
Research & Development (R&D) Contracts	\$888,211,673	16.6%
Buildings and Facilities	\$30,000,000	0.6%
Construction Contracts	\$0	0.0%
Subtotal Contracts	\$918,211,673	17.2%
Research Project Grants (RPGs)	\$3,129,796,011	58.5%
Cancer Centers/Specialized Centers/SPOREs	\$606,359,172	11.3%
NRSA	\$89,878,259	1.7%
Other Research Grants	\$606,416,274	11.3%
Subtotal Grants	\$4,432,449,716	82.8%
Total Extramural Funds	\$5,350,661,389	100.0%
Intramural/RMS Funds		\$1,870,255,014
Total NCI		\$7,220,916,403


Obligations by Budget Mechanism and Division

All NIH Institutes and Centers report their actual obligations each fiscal year by budget mechanism. The tables below organize NCI funding by mechanism and division. The number of awards, trainees, or employees for each mechanism, as well as the dollar amount and percent share of the total NCI budget for each funding mechanism is also included.

NCI Obligations by Mechanism

Percent Share of Total NCI Dollars

Fiscal Year 2024



cancer.gov

The mechanism “Other Research” includes the following grants: Career Programs (K Awards), Cancer Education, Clinical Cooperative Groups, Pre-Doc Post-Doc Transition Awards, Education Projects - Cooperative Agreements, Minority Biomedical Research Support, Research Pathway in Residency, Pilot Research Project, Resource Grants, International Research Training grants, Cooperative Conference Agreements, Conference grants, and Other Transaction Authority (OTA).

NCI OBLIGATIONS BY MECHANISM, FY 2024

(Whole Dollars)

Type of Mechanism	Mechanism	Number	Amount	% of Total Amount
Research Project Grants (RPGs)	Non-Competing	4,136	\$2,286,467,147	31.7%
	Administrative Supplements	438	\$47,845,108	0.7%
	Competing	1,224	\$637,029,310	8.8%
	Subtotal, without SBIR/STTR Grants	5,798	\$2,971,341,565	41.1%
	SBIR/STTR Grants	199	\$158,454,446	2.2%
	Subtotal, RPGs	5,997	\$3,129,796,011	43.3%
Centers & SPOREs	Cancer Centers Grants-P20/P30	83	\$352,357,375	4.9%
	SPOREs	68	\$111,275,432	1.5%
	Other P50s/P20s	0	\$5,105,142	0.1%
	Other Specialized Centers	97	\$137,621,223	1.9%
	Subtotal, Centers	248	\$606,359,172	8.4%
Other Research	Career Program	0	\$0	0.0%
	Post-Doc-Fellow Awards-K00	87	\$8,594,008	0.1%
	Research Scientist Development Award-K01	31	\$4,894,207	0.1%

(Continued from previous page)

Type of Mechanism	Mechanism	Number	Amount	% of Total Amount
Other Research	Academic/Teacher Award-K07	0	\$0	0.0%
	Clinical Investigator-K08	270	\$62,528,453	0.9%
	Physician Scientist Award (Program)-K12	28	\$16,772,145	0.2%
	Transitional Career Development-K22	57	\$10,175,821	0.1%
	Mentored Quant. Res Career-K25	3	\$532,509	0.0%
	Early Stage Mentored Research and Career Development-K38	2	\$204,439	0.0%
	International Research Career Development Award-K43	6	\$402,742	0.0%
	Career Transition Award-K99	75	\$10,590,692	0.1%
	Subtotal, Career Program	559	\$114,695,016	1.6%
	Cancer Education Program-R25 (including BD2K)	83	\$23,600,697	0.3%
Clinical Cooperative Groups-U10/UG1	125	\$302,941,755	4.2%	
PreDoc PostDoc Transition Awards-F99	0	\$1,865,834	0.0%	
UE5 Education Projects	0	\$696,473	0.0%	

(Continued from previous page)

Type of Mechanism	Mechanism	Number	Amount	% of Total Amount
Other Research	Minority Biomedical Support-S06	0	\$2,637,067	0.0%
	Research Pathway in Residency-R38	0	\$1,209,461	0.0%
	Other Transaction Authority-OT2	0	\$33,182,197	0.5%
	Resource Grants-R24/U24/U2C	0	\$121,424,554	1.7%
	Cooperative Conference Agreements-U13/R13	0	\$993,994	0.0%
	International Research Training Grants-D43	0	\$2,469,226	0.0%
	International Training Cooperative Agreement -U2R	0	\$700,000	0.0%
	Subtotal, Career and Other Research Grants		767	\$606,416,274
Subtotal, Research Grants		7,012	\$4,342,571,457	60.1%
National Research Service Award (NRSA) Fellowships	<i>Trainees</i>	1,416	\$89,878,259	1.2%

(Continued from previous page)

Type of Mechanism	Mechanism	Number	Amount	% of Total Amount
R&D Contracts	R&D Contracts	404	\$785,908,607	10.9%
	SBIR Contracts	40	\$33,124,877	0.5%
	NIH Management Fund/ SSF Assessment	0	\$69,178,189	1.0%
	Subtotal, Contracts	444	\$888,211,673	12.3%
Intramural Research	Program	1,873	\$1,036,573,544	14.4%
	NIH Management Fund/ SSF Assessment	0	\$308,819,457	4.3%
	Subtotal, Intramural Research (FTEs)	1,873	\$1,345,393,001	18.6%
Research Management & Support (RMS)	Research Management and Support (RMS)	1,425	\$399,339,819	5.5%
	SBIR RMS	0	\$4,487,150	0.1%
	NIH Management Fund/ SSF Assessment	0	\$121,035,044	1.7%
	Subtotal, RMS (FTEs)	1,425	\$524,862,013	7.3%
Buildings & Facilities		0	\$30,000,000	0.4%
*Total NCI	(FTEs)	3,298	\$7,220,916,403	100.0%

All items in italics are non-add entries.

Division Obligations by Mechanism

DIVISION OBLIGATIONS

Total Division Obligations, FY 2024

(Whole Dollars)

Division	Total
Center for Cancer Research (CCR)	\$641,825,063
Division of Cancer Epidemiology and Genetics (DCEG)	\$139,536,294
Division of Cancer Treatment and Diagnosis (DCTD)	\$552,026,623
Division of Cancer Biology (DCB)	\$59,593,673
Division of Cancer Control and Population Sciences (DCCPS)	\$157,821,619
Division of Cancer Prevention (DCP)	\$237,232,654
Division of Extramural Activities (DEA)	\$23,102,950
Office of the Director (OD)	\$1,700,717,388
Total Division	\$3,511,856,354

CENTER FOR CANCER RESEARCH (CCR)

CCR Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Intramural Research	Program	\$641,825,063
	NIH Management Fund/ SSF Assessment	\$0
Total CCR		\$641,825,063

DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS (DCEG)

DCEG Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
R&D Contracts	R&D Contracts	\$44,087,333
	SBIR Contracts	\$0
Intramural Research	Program	\$95,448,961
	NIH Management Fund/ SSF Assessment	\$0
Total DCEG		\$139,536,294

DIVISION OF CANCER TREATMENT AND DIAGNOSIS (DCTD)

DCTD Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Centers & SPORES	Cancer Centers Grants-P20/P30	\$0
	SPORES-P50	\$110,789,224
	Other P50s/P20s	\$0
	Other Specialized Centers	\$16,072,162
	Subtotal, Centers	\$126,861,386

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
Other Research–Grants	Cancer Education Program-R25 (including BD2K)	\$0
	Education Projects-UE5	\$0
	Clinical Cooperative Groups-U10/UG1	\$142,141,328
	PreDoc PostDoc Transition Awards-F99	\$0
	Minority Biomedical Support-S06	\$0
	Research Pathway in Residency-R38	\$0
	Pilot Research Project-OT2	\$0
	Resource Grants-R24/U24/U2C	\$0
	Cooperative Conference Agreements-U13/R13	\$0
	International Research Training Grants-D43/U2R	\$0
	Subtotal, Other Research-Grants	\$142,141,328
Subtotal, Research Grants		\$269,002,714

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
R&D Contracts	R&D Contracts	\$215,884,882
	SBIR Contracts	\$0
	NIH Management Fund/SSF Assessment	\$0
	Subtotal, Contracts	\$215,884,882
Research Management & Support (RMS)	RMS	\$67,139,027
	SBIR RMS	\$0
	NIH Management Fund/SSF Assessment	\$0
	Subtotal, RMS	\$67,139,027
Total DCTD		\$552,026,623

DIVISION OF CANCER BIOLOGY (DCB)

DCB Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Centers & SPOREs	Cancer Centers Grants-P20/P30	\$0
	SPOREs-P50	\$0
	Other P50s/P20s	\$375,635
	Other Specialized Centers	\$43,852,991
	Subtotal, Centers	\$44,228,626
Other Research-Grants	Subtotal, Other Research-Grants	\$0
Subtotal, Research Grants		\$44,228,626
R&D Contracts	R&D Contracts	\$0
	SBIR Contracts	\$0
	NIH Management Fund/SSF Assessment	\$0
	Subtotal, Contracts	\$0
Research Management & Support (RMS)	RMS	\$15,365,047
	SBIR RMS	\$0
	NIH Management Fund/SSF Assessment	\$0
	Subtotal, RMS	\$15,365,047
Total DCB		\$59,593,673

DIVISION OF CANCER CONTROL AND POPULATION SCIENCES (DCCPS)

DCCPS Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Centers & SPOREs	Cancer Centers Grants-P20/P30	\$0
	SPOREs-P50	\$0
	Other P50s/P20s	\$4,346,416
	Other Specialized Centers	\$9,243,218
	Subtotal, Centers	\$13,589,634
Other Research	Cancer Education Program-R25 (including BD2K)	\$0
	Education Projects-UE5	\$0
	Clinical Cooperative Groups-U10/UG1	\$0
	PreDoc PostDoc Transition Awards-F99	\$0
	Minority Biomedical Support-S06	\$0
	Research Pathway in Residency-R38	\$0
	Pilot Research Project-OT2	\$0
	Resource Grants-R24/U24/U2C	\$0
	Cooperative Conference Agreements-U13/R13	\$0
	International Research Training Grants-D43/U2R	\$0
	Subtotal, Other Research	\$0
Subtotal, Research Grants	\$13,589,634	

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
R&D Contracts	R&D Contracts	\$100,630,059
	SBIR Contracts	\$0
	NIH Management Fund/ SSF Assessment	\$0
	Subtotal, Contracts	\$100,630,059
Research Management & Support (RMS)	RMS	\$43,601,926
	SBIR RMS	\$0
	NIH Management Fund/ SSF Assessment	\$0
	Subtotal, RMS	\$43,601,926
Total DCCPS		\$157,821,619

DIVISION OF CANCER PREVENTION (DCP)

DCP Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Centers & SPOREs	Cancer Centers Grants-P20/P30	\$0
	SPOREs-P50	\$0
	Other P50s/P20s	\$0
	Other Specialized Centers	\$10,199,405
	Subtotal, Centers	\$10,199,405
Other Research–Grants	Cancer Education Program-R25 (including BD2K)	\$0
	Education Projects- UE5	\$0
	Clinical Cooperative Groups-U10/UG1	\$153,530,193
	PreDoc PostDoc Transition Awards-F99	\$0
	Minority Biomedical Support-S06	\$0
	Research Pathway in Residency-R38	\$0
	Pilot Research Project-OT2	\$0
	Resource Grants-R24/U24/U2C	\$0
	Cooperative Conference Agreements-U13/R13	\$0
	International Research Training Grants-D43/U2R	\$0
Subtotal, Other Research Grants	\$153,530,193	

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
Subtotal, Research Grants		\$163,729,598
R&D Contracts	R&D Contracts	\$42,914,835
	SBIR Contracts	\$0
	NIH Management Fund/SSF Assessment	\$0
	Subtotal, Contracts	\$42,914,835
Research Management & Support (RMS)	RMS	\$30,588,221
	SBIR RMS	\$0
	NIH Management Fund/SSF Assessment	\$0
	Subtotal, RMS	\$30,588,221
Total DCP		\$237,232,654

DIVISION OF EXTRAMURAL ACTIVITIES (DEA)

DEA Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Research Management & Support (RMS)	RMS	\$23,102,950
	SBIR RMS	\$0
	NIH Management Fund/ SSF Assessment	\$0
Total DEA		\$23,102,950

OFFICE OF THE DIRECTOR (OD)

OD Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Research Project Grants (RPGs)	Non-Competing	\$0
	Administrative Supplements	\$0
	Competing	\$0
	Subtotal, without SBIR/STTR Grants	\$0
	SBIR/STTR Grants-R41 -44	\$158,454,446
	Subtotal, RPGs	\$158,454,446

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
Centers & SPOREs	Cancer Centers Grants-P20/P30	\$352,357,375
	SPOREs-P50	\$486,208
	Other P50s/P20s	\$383,091
	Other Specialized Centers	\$58,253,447
	Subtotal, Centers	\$411,480,121
Other Research–Career Program	Post-Doc-Fellow Awards-K00	\$8,594,008
	Research Scientist Development Award-K01	\$4,894,207
	Research Scientist Award-K05	\$0
	Academic/Teacher Award-K07	\$0
	Clinical Investigator-K08	\$62,528,453
	Physician Scientist Award (Program)-K12	\$16,772,145
	Transitional Career Development-K22	\$10,175,821
	Mentored Patient Oriented RCDA-K23	\$0
	Mid-Career Invest. & Patient Orient. Res-K24	\$0
	Mentored Quant. Res Career-K25	\$532,509
Early Stage Mentored Research and Career Development-K38	\$204,439	

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
Other Research–Career Program	International Research Career Development Award-K43	\$402,742
	Career Transition Award-K99	\$10,590,692
	Subtotal, Career Program	\$114,695,016
Other Research–Grants	Cancer Education Program-R25 (including BD2K)	\$23,600,697
	Education Projects-UE5	\$0
	Clinical Cooperative Groups-U10/UG1	\$7,270,234
	PreDoc PostDoc Transition Awards-F99	\$0
	Minority Biomedical Support-S06	\$0
	Rsrch Pathway in Residency-R38	\$0
	Pilot Research Project-OT2	\$0
	Resource Grants-R24/U24/U2C	\$0
	Cooperative Conference Agreements-U13/R13	\$0
	International Research Training Grants-D43/U2R	\$0
	Subtotal, Other Research–Grants	\$30,870,931
Subtotal, Research Grants		\$715,500,514

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
NRSA Fellowships		\$87,791,141
R&D Contracts	R&D Contracts	\$310,971,538
	SBIR Contracts	\$33,124,877
	NIH Management Fund/ SSF Assessment	\$0
	Subtotal, Contracts	\$344,096,415
Intramural Research	Program	\$299,299,520
	NIH Management Fund/ SSF Assessment	\$0
	Subtotal, Intramural Research	\$299,299,520
Research Management & Support (RMS)	RMS	\$219,542,648
	SBIR RMS	\$4,487,150
	NIH Management Fund/ SSF Assessment	\$0
	Subtotal, RMS	\$224,029,798
Buildings and Facilities		\$30,000,000
Total OD		\$1,700,717,388

NIH Management Fund, Service and Supply Fund (SSF), and GSA Rent

The NIH Management Fund provides the financing for certain common research and administrative support activities that are required in the operations of NIH:

Clinical Center: Admissions and follow-up, anesthesiology, diagnostic x-ray, nuclear medicine, clinical pathology, blood bank, rehabilitation medicine, pharmacy, medical records, nursing services, patient nutrition services, housekeeping services, laundry, social work, drug costs, red team response, bench to bedside, and the children's hospital.

Center for Scientific Review: Initial scientific review of applications and assignment of research grant applications to institutes.


Center for Information Technology: Research and development program that applies concepts and methods of computer science are applied to biomedical problems.

Other Research Services: Procurement, safety, engineering, biomedical engineering, veterinary resources, and library services have moved to Service and Supply fund.

Service & Supply Fund: Mainframe computing, enterprise IT software planning and development, engineering planning and design, printing, telecommunications, procurement, shipping and receiving, motor pool, research animals, fabrication and maintenance of scientific equipment, utilities and plant maintenance, biomedical engineering, background investigations, IT cybersecurity, and General Services Administration (GSA) rental payments for space (including all building rental costs, utilities and guard services) and Other Research Services (to include procurement, safety, engineering and biomedical engineering).

NIH Management Fund, Service & Supply Fund, and GSA Rent

Fiscal Year 2024



cancer.gov

NCI FY 2024 MANAGEMENT FUND, SSF, AND GSA RENT

(Whole Dollars)

Distribution of NCI Payment	Amount	Share of NCI
Clinical Center	\$200,170,867	39.0%
Center for Scientific Review	\$22,983,336	4.5%
Center for Information Technology	\$42,428,424	8.3%
Service & Supply Fund Assessment	\$247,660,891	48.3%
Other Research Services	\$0	0.0%
Other OD	\$0	0.0%
Total NCI Management Fund & SSF	\$513,243,518	100.0%

NIH FY 2024 MANAGEMENT FUND & SSF

(Whole Dollars)

Type	Amount	Percent
NCI	\$513,243,518	20.2%
All Other NIH Institutes	\$2,026,027,574	79.8%
Total NIH Management Fund & SSF	\$2,539,271,091	100%

Special Sources of Funds

Cooperative Research and Development Agreements (CRADAs)

As a result of the Federal Technology Transfer Act of 1986 (PL 99-502), government laboratories are authorized to enter into Cooperative Research and Development Agreements (CRADAs) with private sector entities. Under a CRADA, the NIH laboratory can provide personnel, services, facilities, equipment, or other resources and the collaborator can provide funds, personnel, services, facilities, equipment or other material and/or technical resources. Importantly, the CRADA provides the non-Federal party the option to negotiate an exclusive license to the resultant CRADA Subject Invention(s). The CRADA is the primary legal mechanism the Federal government has to convey such rights in advance of an invention. The agreement has no mandatory length but often are written for 1 to 3 years, renewable at the mutual agreement of the parties.

NCI CRADA RECEIPTS DEPOSITED TO THE U.S. TREASURY

(Dollars in Thousands)

Fiscal Year	Carryover from Prior Year	Collections	Obligations
2006	\$13,567	\$6,142	\$7,125
2007	\$12,584	\$9,410	\$8,360
2008	\$13,634	\$6,677	\$7,200
2009	\$13,111	\$5,466	\$4,765
2010	\$13,813	\$5,024	\$5,644
2011	\$13,150	\$8,582	\$5,894
2012	\$15,504	\$9,253	\$5,668
2013	\$10,587	\$11,226	\$8,470
2014	\$21,173	\$9,334	\$5,672
2015	\$24,835	\$15,772	\$11,670
2016	\$28,276	\$23,411	\$17,259
2017	\$40,647	\$27,033	\$20,990
2018	\$46,311	\$28,601	\$22,936

(Continued from previous page)

Fiscal Year	Carryover from Prior Year	Collections	Obligations
2019	\$50,978	\$32,899	\$28,178
2020	\$53,825	\$33,776	\$28,683
2021	\$59,044	\$38,735	\$32,994
2022	\$71,091	\$22,856	\$11,301
2023	\$67,363	\$34,102	\$37,834
2024	\$80,655	\$34,633	\$22,152

Royalty Income

NCI retains a portion of the royalty income generated by the patents related to NCI-funded research. A major portion of this royalty income is used to support employees of the laboratory, further scientific exchange, and provide education and training in accordance with the terms of the Federal Technology Transfer Act (PL 99-502). Receipts are also used to support costs associated with processing and collecting royalty income and for technology transfer efforts at NCI and NIH. Royalties may be spent in the year of receipt and for two additional fiscal years.

NCI ROYALTY INCOME FUNDING HISTORY

(Dollars in Thousands)

Years	Collections*	Inventor Payments	Other Obligations
1991/1992	\$2,084	\$431	\$1,653
2001/2003	\$27,443	\$6,210	\$21,233
2005/2007	\$34,086	\$5,745	\$28,341
2006/2008	\$29,811	\$6,853	\$22,958
2007/2009	\$36,344	\$7,210	\$29,134
2008/2010	\$50,269	\$8,192	\$42,077
2009/2011	\$51,621	\$10,225	\$41,396
2010/2012	\$58,515	\$5,729	\$52,786

(Continued from previous page)

Years	Collections*	Inventor Payments	Other Obligations
2011/2013	\$69,155	\$23,271	\$45,884
2012/2014	\$84,876	\$33,279	\$51,597
2013/2015	\$91,324	\$48,433	\$42,891
2014/2016	\$112,668	\$33,487	\$79,181
2015/2017	\$122,037	\$30,605	\$91,432
2016/2018	\$115,096	\$27,316	\$87,780
2017/2019	\$112,611	\$27,233	\$85,378
2018/2020	\$86,231	\$15,539	\$70,692
2019/2021	\$70,400	\$5,370	\$65,030
2020/2022	\$24,541	\$7,244	\$17,297
2021/2023	\$34,142	\$6,130	\$28,012
2022/2024	\$42,709	\$5,506	\$37,203
² 2023/2025	\$34,856	\$7,070	\$27,786
² 2024/2026	\$35,510	\$6,000	\$29,510

* Collections do not include assessments by NIH.

² Inventor Payments and Other Obligations are estimates.

Stamp Out Breast Cancer Act

The Stamp Out Breast Cancer Act (PL 105-41) was enacted in August 1997 and has since been extended to July 2000 (PL 106-253), November 2005 (PL 109-100), December 2007 (PL 110-150), December 2011 (PL 112-80), December 2015 (PL 114-99) and recently until December 2027 (PL 116-92). This act allows postal customers the opportunity to contribute funds to breast cancer research through their voluntary purchases of special rate postage stamps from the U.S. Postal Service (USPS). The act requires the USPS to transfer 70% of the funds collected (after postage costs and administrative costs) to the NIH and 30% to the Department of Defense. As of September 2024, NCI has received \$67,594,833. NCI uses these funds for research projects directed towards breast cancer research. Thus far, several major programs have been funded, including the Insight Awards to Stamp Out Breast Cancer, the Breast Cancer Research Stamp Exceptional Opportunities Program, the Breast Cancer Premalignancy Program, a clinical trial to determine the risk of breast cancer recurrence, the Molecular and Cellular Characterization of Screen Detected Lesions Consortium, the Breast Cancer Weight Loss (BWEL), and the Tomosynthesis Mammographic Imaging Screening Trial (TMIST). In fiscal year 2024, \$564,728 in stamp funds were obligated towards breast cancer research.

NCI BREAST CANCER STAMP FUNDING HISTORY

(Dollars in Thousands)

FY	Collected	Obligated	*Balance
1999	\$4,150	\$0	\$4,150
2000	\$3,101	\$3,499	\$3,753
2001	\$5,556	\$4,846	\$4,463
2002	\$3,595	\$1,129	\$6,929
2003	\$5,176	\$3,130	\$8,975
2004	\$4,814	\$3,472	\$10,317
2005	\$4,372	\$2,987	\$11,703
2006	\$4,468	\$6,896	\$9,274
2007	\$3,006	\$1,601	\$10,679
2008	\$4,856	\$2,122	\$13,413
2009	\$3,403	\$1,873	\$14,944

(Continued from previous page)

FY	Collected	Obligated	*Balance
2010	\$2,345	\$2,590	\$14,698
2011	\$2,049	\$1,977	\$14,770
2012	\$1,623	\$1,654	\$14,738
2013	\$1,404	\$1,337	\$14,805
2014	\$1,160	\$1,477	\$14,488
2015	\$1,251	\$1,635	\$14,105
2016	\$1,707	\$1,654	\$14,158
2017	\$1,387	\$1,640	\$13,905
2018	\$1,294	\$5,349	\$16,497
2019	\$1,450	\$2,518	\$15,429
2020	\$1,060	\$2,571	\$13,918
2021	\$1,112	\$1,000	\$14,030
2022	\$1,221	\$1,461	\$13,791
2023	\$1,028	\$3,423	\$11,395
2024	\$1,008	\$565	\$11,839

**Balance includes carryover funds from the prior fiscal year that have not been obligated.*

Funding for Research Areas

NCI reports how appropriated funds are spent based on their category or classification. These include funding for specific cancer sites, cancer types, diseases related to cancer, as well as types of NCI research mechanisms. The table below identifies funding levels for frequently requested areas of cancer research.

The research areas in this table do not represent the entire NCI research portfolio. Moreover, funding for research areas often overlaps, and therefore the total for all research areas does not equal the total NCI budget. For example, funding for a clinical trial on breast cancer would be included in both the “Breast Cancer” and the “Clinical Trials” lines in the table below. Similarly, a basic cancer research project may be relevant to cervical, uterine, and ovarian cancers, and the relevant amounts would be included in the amounts for all three areas of cancer research. NCI provides estimated amounts based on initial budget data before final reconciliation is completed. After this analysis is done, the figures for years that often vary slightly from previously reported estimates are marked “Actual”.

FUNDING BY RESEARCH AREAS

(Dollars in Millions)

Disease Area	2018 Actual	2019 Actual	2020 Actual	2021 Actual	2022 Estimate	2023 Estimate	2024 Estimate
Total NCI Budget	\$5,636.4	\$5,927.7	\$5,992.3	\$6,383.3	\$6,467.0	\$6,833.6	\$7,221.1
AIDS	249.0	241.2	242.0	242.0	248.9	258.9	269.5
Brain & CNS	219.8	220.9	231.7	595.1	251.1	261.1	236.1
Breast Cancer	545.1	574.9	545.3	514.6	558.3	580.6	542.0
Cervical Cancer	68.0	71.5	86.0	69.3	73.7	76.6	20.7
Clinical Trials	806.6	889.8	794.3	843.0	824.6	857.6	852.3
Colorectal Cancer	208.4	256.0	238.8	211.6	248.0	257.9	238.6

(Continued from previous page)

Disease Area	2018 Actual	2019 Actual	2020 Actual	2021 Actual	2022 Estimate	2023 Estimate	2024 Estimate
Head and Neck Cancers	63.6	62.1	71.5	49.7	69.0	55.1	69.9
Hodgkin Lymphoma	13.0	13.3	12.2	14.3	15.9	16.5	7.3
Leukemia	250.5	258.3	256.6	244.5	276.0	287.0	270.6
Liver Cancer	72.7	94.6	107.8	96.3	111.5	116.0	114.2
Lung Cancer	320.6	350.1	418.4	402.8	459.0	477.4	435.0
Melanoma	153.2	158.4	191.9	155.6	179.2	186.4	157.4
Multiple Myeloma	60.7	61.5	58.2	43.3	51.3	53.4	55.0
Non-Hodgkin Lymphoma	119.5	121.0	120.4	119.5	137.7	143.2	117.0
Ovarian Cancer	109.8	120.8	121.5	116.5	134.7	140.1	132.0
Pancreatic Cancer	178.3	182.1	187.0	178.5	218.1	226.8	246.0
Prostate Cancer	233.0	239.1	244.8	209.4	269.7	280.5	258.6
Stomach Cancer	13.4	14.2	14.8	10.6	15.4	16.0	33.0

Disease Area	2018 Actual	2019 Actual	2020 Actual	2021 Actual	2022 Estimate	2023 Estimate	2024 Estimate
Uterine Cancer	17.5	17.5	17.9	13.6	14.4	15.0	20.0

These figures were created using NCI's coding methodology. More information about this methodology, as well as the research projects associated with these and other disease area categories, are available on the [NCI Funded Research Portfolio](#) website.


The fiscal year 2023 funds available to NCI totaled \$7.2 billion (including \$216 million in Cures Act funding), reflecting an increase of 5.7%, or \$387.5 million from the previous fiscal year. For more information on NCI's grant funding policy, visit the [NCI Division of Extramural Affairs](#) website.

NCI Extramural Programs

The NCI uses most of its budget to fund extramural grants and contracts. The following links provide information about the most recent Fiscal Year extramural funding by grant activity, institution, state, and country.

Research Project Grants (RPGs)

In fiscal year 2024, more than 72.5% of competing funds were used to support grants awarded either within the established payline or through Requests for Applications (RFAs). Of the total competing dollars, 12.4% specifically supported RFA-driven awards. The remaining funds were used to support grants made as exceptions to the standard funding range.



Includes Small Business Innovation Research and Small Business Technology Transfer Awards.
FY 2020 - 2023 Includes Cancer MoonshotSM Funding.

RPGs Summary, Fiscal Years 2023–2024

RPG AWARDS FUNDED

(Dollars in Thousands)

RPG Awards Funded	2023 No. or %	2023 Amount	2024 No. or %	2024 Amount
Total Funding for RPGs	6,090	\$3,145,237	6,175	\$3,129,796
SBIR/STTR	228	\$175,373	199	\$158,454
Funding for RPGs without SBIR/STTR Program	5,862	\$2,969,864	5,976	\$2,971,342
Continuation or Noncompeting Grants Funded	4,139	\$2,125,093	4,316	\$2,174,188
Competing Grants Funded	1,369	\$697,786	1,224	\$640,639
Administrative Supplements	354	\$39,659	436	\$47,330
Partial Assessment for DHHS Program Evaluation		\$107,326		\$109,184

FUNDS SET ASIDE WITHIN COMPETING DOLLARS

(Dollars in Thousands)

Grant Category	R01 or Share	2023 No. or %	2023 Amount	2024 No. or %	2024 Amount
Grants within Paylines		1018	\$481,920	888	\$420,190
	Traditional R01	776	\$428,468	616	\$347,693
RFA Grants		115	\$71,919	108	\$79,166

(Continued from previous page)

Grant Category	R01 or Share	2023 No. or %	2023 Amount	2024 No. or %	2024 Amount
	Share of Competing Grant Funds	10.3%		12.4%	
Exception Grants		351	\$215,866	336	\$220,450
	Share of Competing Grant Funds	30.9%		34.4%	


COMPETING RPGS

Statistical Measure	2023	2024
Total Competing Application Requests*	8,618	8,990
Funding Success Rate	16%	14%
Percentile Funding for R01 Grants	12th & 17th	10th & 17th
Average Cost-Competing	\$510	\$523
Average Reduction from Recommended/Requested Levels	-14%	-14%

*Excludes SBIR/STTR

RPGs Funding Mechanisms

Percent Share of Total RPG Funds, FY 24



cancer.gov

The "Other" category includes DP1, DP2, DP5, R00, R37, U01, U19, UH2, UH3, UG3, UA5, R50, UM1, R15, R55 and R56 activities.

GRANT FUNDING PAYLINES

RPG Mechanism	2023	2024	Description
R01 Traditional Grants	12th & 17th	10th & 17th	Percentile
P01 Program Projects	17% Reduction	17% Reduction	SPL Selected*
R03 Small Grants	25	25	Impact Score
R15 Academic Research	25	25	Impact Score
R21 Exploratory Phase I	9th	10th	Percentile
R33 Exploratory Phase II	N/A	N/A	SPL Selected*
R41/R42 STTR	26	25	Impact Score
R43/R44 SBIR	27	25	Impact Score

*SPL = Scientific Program Leaders (NCI)

RPGs Requested and Awarded

The following table displays requested and awarded RPGs and the success rate for fiscal years 2023 and 2024. These numbers include Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awards. The Download the Data link contains data for the prior ten years.

RPGs REQUESTED, AWARDED, AND SUCCESS RATE

(Dollars in Thousands)

Fiscal Year	Type	Number Requested	Amount Requested	Number Awarded	Amount Awarded	Success Rate
2023	Competing New	9,302	\$4,888,297,784	1,319	\$653,918	15.4%
	Competing Renewal	427	\$341,237,643	179	\$130,281	
	Competing Supplement			0	\$0	
	Competing Subtotal	9,729	\$5,229,535,427	1,498	\$784,199	
	Non-Competing			4,238	\$2,253,712	
	FY 2023 RPG Total			5,736	\$3,037,911	

(Continued from previous page)

Fiscal Year	Type	Number Requested	Amount Requested	Number Awarded	Amount Awarded	Success Rate
2024	Competing New	9,932	\$5,470,395	1,177	\$608,278	12.8%
	Competing Renewal	413	\$347,341	145	\$100,450	
	Competing Supplement	8	\$2,005	3	\$515	
	Competing Subtotal	10,353	\$5,819,741	1,325	\$709,243	
	Non-Competing			4,414	\$2,311,369	
	FY 2024 RPG Total			5,739	\$3,020,612	

Includes Small Business Innovation Research and Small Business Technology Transfer (SBIR/STTR) Awards.

FY 2020-2023 figures include Cancer MoonshotSM funding data.

Success rate is the number of awarded grants divided by the number of awards requested.

Includes FY 2023 Cancer Moonshot funding. Excludes FY 2017 through FY2022 Moonshot carryover obligations.

RPG Awards by Grant Activity Codes

This table displays awarded research project grants (RPG) data by grant activity code and count. Please visit [NIH Activity Codes](#) for more information on the descriptions.

RPGs AVERAGE COST, FY 2014–2024

(Dollars in Thousands)

Year	Total No. Awarded	Total Amount	Average Cost
2014	4,814	\$1,939,623	\$403
2015	4,767	\$2,019,308	\$424
2016	4,666	\$2,068,869	\$443
2017	4,663	\$2,195,184	\$471
2018	4,780	\$2,366,530	\$495
2019	4,984	\$2,456,156	\$493
2020	5,070	\$2,677,206	\$514
2021	5,221	\$2,739,345	\$525
2022	5,505	\$2,871,997	\$522
2023	5,736	\$3,037,911	\$530
2024	5,739	\$3,020,612	\$526

RPG AWARDS BY GRANT ACTIVITY CODES, FY 2023–2024

(Dollars in Thousands)

Grant Code	2023 Number	2023 Amount	2024 Number	2024 Amount
R01	3,725	\$1,864,401	3,698	\$1,842,927
DP1	0	\$0	2	\$1,090
DP2	0	\$356	0	\$20
DP5	0	\$0	0	\$0
P01	96	\$197,631	90	\$187,561
R00	104	\$25,555	115	\$28,296
R37	343	\$164,733	381	\$180,953
U01	321	\$236,674	333	\$234,896
U19	7	\$12,552	10	\$15,494
U34	1	\$284	2	\$564
UH2	5	\$1,057	4	\$937
R34	3	\$881	15	\$4,384
R35	133	\$127,082	120	\$112,120
R50	94	\$16,474	111	\$19,286
UH3	30	\$24,463	29	\$22,827
UA5	0	\$0	0	\$0
UM1	21	\$53,731	19	\$55,120
UG3	3	\$4,126	18	\$16,176
R03	108	\$9,508	102	\$10,375
R21	433	\$93,605	395	\$96,400
R33	43	\$16,046	47	\$16,996
R15	20	\$9,050	20	\$9,213

(Continued from previous page)

Grant Code	2023 Number	2023 Amount	2024 Number	2024 Amount
R55	0	\$0	0	\$0
R56	5	\$1,220	4	\$1,006
R61	13	\$3,108	25	\$5,515
RC2	0	\$0	0	\$0
SBIR/STTR	228	\$175,373	199	\$158,454
Total	5,736	\$3,037,911	5,739	\$3,020,612

Grants to NCI-Designated Cancer Centers

NCI-Designated Cancer Centers are institutions dedicated to research to develop more effective approaches to prevent, diagnose, and treat cancer. [Find an NCI-Designated Cancer Center](#) near you and learn about its patient services and research capabilities.

The grant count and amounts include multi-year funded awards and the fiscal year 2023 Cancer Moonshot funds, excludes carryover obligations for fiscal years 2017 through 2022.

NCI-DESIGNATED CANCER CENTER TOTALS, FISCAL YEAR 2024

(Dollars in Thousands)

Mechanism	Count	Amount
Total P30 Core Grants	72	\$345,481
Planning Grants (P20s)	8	\$1,712
Other Cancer Center Grants	0	\$5,169
Total Cancer Centers	80	\$352,362

NCI-DESIGNATED CANCER CENTERS BY STATE (P30 CORE GRANTS), FISCAL YEAR 2024

(Dollars in Thousands)

State	Grantee Institution	Code	Count	Amount
Alabama	University of Alabama at Birmingham	Comprehensive Core	1	\$6,308
Arizona	University of Arizona	Comprehensive Core	1	\$3,937
California	Beckman Research Institute/City of Hope	Comprehensive Core	1	\$4,316
	Salk Institute for Biological Studies	Basic Core	1	\$3,029
	Sanford Burnham Prebys Medical Discovery Institute	Basic Core	1	\$4,082
	Stanford University	Comprehensive Core	1	\$4,496
	University of California, Davis	Comprehensive Core	1	\$3,572
	University of California, Los Angeles	Comprehensive Core	1	\$6,200
	University of California, San Diego	Comprehensive Core	1	\$5,025
	University of California, San Francisco	Comprehensive Core	1	\$8,130
	University of California, Irvine	Comprehensive Core	1	\$2,350
	University of Southern California	Comprehensive Core	1	\$6,880

(Continued from previous page)

State	Grantee Institution	Code	Count	Amount
Colorado	University of Colorado, Denver	Comprehensive Core	1	\$4,888
Connecticut	Yale University	Comprehensive Core	1	\$5,742
District of Columbia	Georgetown University	Comprehensive Core	1	\$2,105
Florida	H. Lee Moffitt Cancer Center & Research Institute	Comprehensive Core	1	\$4,518
	University of Florida	Clinical Core	1	\$2,135
	University of Miami School of Medicine	Clinical Core	1	\$3,019
Georgia	Emory University	Comprehensive Core	1	\$3,267
Hawaii	University of Hawai'i at Manoa	Clinical Core	1	\$2,378
Illinois	Northwestern University at Chicago	Comprehensive Core	1	\$6,341
	University of Chicago	Comprehensive Core	1	\$4,524
Indiana	Indiana University at Indianapolis	Comprehensive Core	1	\$3,344
	Purdue University	Basic Core	1	\$1,860

(Continued from previous page)

State	Grantee Institution	Code	Count	Amount
Iowa	University of Iowa	Comprehensive Core	1	\$2,985
Kansas	University of Kansas Medical Center	Comprehensive Core	1	\$2,809
Kentucky	University of Kentucky	Comprehensive Core	1	\$2,860
Maine	Jackson Laboratory	Basic Core	1	\$2,246
Maryland	Johns Hopkins University	Comprehensive Core	1	\$8,084
	University of Maryland Baltimore	Comprehensive Core	1	\$2,817
Massachusetts	Dana-Farber Cancer Institute	Comprehensive Core	1	\$13,070
	Massachusetts Institute of Technology	Basic Core	1	\$3,755
Michigan	University of Michigan at Ann Arbor	Comprehensive Core	1	\$8,085
	Wayne State University	Comprehensive Core	1	\$2,884
Minnesota	Mayo Clinic in Rochester	Comprehensive Core	1	\$5,930
	University of Minnesota	Comprehensive Core	1	\$4,378
Missouri	Washington University	Comprehensive Core	1	\$6,527

(Continued from previous page)

State	Grantee Institution	Code	Count	Amount
Nebraska	University of Nebraska Medical Center	Clinical Core	1	\$2,894
New Hampshire	Dartmouth College	Comprehensive Core	1	\$3,388
New Jersey	Rutgers Biomedical and Health Sciences	Comprehensive Core	1	\$3,764
New Mexico	University of New Mexico Health Science Center	Comprehensive Core	1	\$2,652
New York	Albert Einstein College of Medicine Yeshiva University	Comprehensive Core	1	\$3,900
	Cold Spring Harbor Laboratory	Basic Core	1	\$4,495
	Columbia University Health Sciences	Comprehensive Core	1	\$5,568
	Icahn School of Medicine at Mount Sinai	Clinical Core	1	\$2,948
	New York University School of Medicine	Comprehensive Core	1	\$4,196
	Roswell Park Cancer Institute Corp	Comprehensive Core	1	\$4,669
	Memorial Sloan Kettering Institute for Cancer Research	Comprehensive Core	1	\$13,458

(Continued from previous page)

State	Grantee Institution	Code	Count	Amount
North Carolina	Duke University	Comprehensive Core	1	\$6,372
	University of North Carolina Chapel Hill	Comprehensive Core	1	\$8,179
	Wake Forest University Health Sciences	Comprehensive Core	1	\$2,690
Ohio	Case Western Reserve University	Comprehensive Core	1	\$5,922
	Ohio State University	Comprehensive Core	1	\$5,977
Oklahoma	University of Oklahoma Health Sciences Center	Clinical Core	1	\$2,413
Oregon	Oregon Health & Science University	Comprehensive Core	1	\$3,083
Pennsylvania	Research Institute of Fox Chase Cancer Center	Comprehensive Core	1	\$0
	Thomas Jefferson University	Clinical Core	1	\$3,108
	University of Pennsylvania	Comprehensive Core	1	\$9,434
	University of Pittsburgh	Comprehensive Core	1	\$6,346
	Wistar Institute	Basic Core	1	\$3,584
South Carolina	Medical University of South Carolina	Clinical Core	1	\$2,363

(Continued from previous page)

State	Grantee Institution	Code	Count	Amount
Tennessee	St. Jude Children's Research Hospital	Comprehensive Core	1	\$7,230
	Vanderbilt University Medical Center	Comprehensive Core	1	\$7,764
Texas	Baylor College of Medicine	Comprehensive Core	1	\$3,767
	University of Texas Health Science Center	Clinical Core	1	\$2,192
	University of Texas MD Anderson Cancer Center	Comprehensive Core	1	\$12,116
	University of Texas Southwestern Medical Center	Comprehensive Core	1	\$4,306
Utah	University of Utah	Comprehensive Core	1	\$4,983
Virginia	University of Virginia	Comprehensive Core	1	\$2,805
	Virginia Commonwealth University	Comprehensive Core	1	\$3,273
Washington	Fred Hutchinson Cancer Research Center	Comprehensive Core	1	\$11,331
Wisconsin	University of Wisconsin-Madison	Comprehensive Core	1	\$5,435
Total P30 Core Grants			72	\$345,481

Specialized Programs of Research Excellence (SPOREs)

In 1992, NCI established the Specialized Programs of Research Excellence (SPOREs). The Translational Research Program (TRP) is the home of the SPOREs, a cornerstone of NCI's efforts to promote collaborative, interdisciplinary translational cancer research. SPORE grants involve both basic and clinical/applied scientists. They support projects that may result in new and diverse approaches to the prevention, early detection, diagnosis, and treatment of human cancers.

Each SPORE focuses on a specific organ site, such as breast or lung cancer, or on a group of highly related cancers, such as gastrointestinal cancers. SPOREs enable the rapid and efficient movement of basic scientific findings into clinical settings and determine the biological basis for observations made in individuals with cancer or in populations at risk for cancer.

For more information on organ sites, please visit the [Translational Research Program](#).

The NCI Funded Research Portfolio (NFRP) web site contains additional information about the SPORE grants listed below that have been funded by NCI. The NFRP provides access to various NCI budget reports that contain information about research funding according to specific research categories.

For more detailed information on these SPORE grants, visit the [NCI Funded Research Portfolio \(NFRP\)](#).

FISCAL YEAR 2024 FUNDING FOR SPORE GRANTS

(Whole Dollars)

Mechanism	Site	Amount
P50 & P20 SPOREs	Bladder	\$896,275
	Brain	\$11,240,582
	Breast	\$11,846,411
	Cervical	\$1,949,494
	Disparities/Breast & Lung	\$1,693,527
	Disparities: GI	\$2,575,782
	Endometrial	\$5,688,927
	Epigenetic	\$2,421,039
	Gastrointestinal	\$896,274
	Head and Neck	\$5,501,419
	Hyperactive RAS	\$2,208,392
	Kidney	\$4,463,070
	Leukemia	\$4,366,789
	Liver	\$2,236,005
	Lung	\$5,553,587
Lymphoma	\$2,075,728	
Multiple Myeloma	\$2,098,348	

(Continued from previous page)

Mechanism	Site	Amount
P50 & P20 SPOREs	Ovarian	\$8,509,129
	Pancreas	\$6,538,889
	Prostate	\$14,662,305
	Radiation	\$1,946,064
	Sarcoma	\$2,375,406
	Skin	\$6,932,849
	Total P50 SPOREs	\$108,676,291
Co-funded	Head & Neck	\$575,000
	Total Co-funded	\$575,000
Total Number of SPOREs, Total SPORE Funding		\$109,251,291

Total funding shown represents the SPORE program using relevant co-funded grants external to NCI.

Dr. Ruth L. Kirschstein National Research Service Awards (NRSA)

This trainee award program is named after Dr. Ruth L. Kirschstein, a polio vaccine researcher and a champion of research training and inclusion of underrepresented individuals in the scientific workforce. Dr. Kirschstein was the first woman to become director of an NIH institute.

The NCI Ruth L. Kirschstein National Research Service Award (NRSA) program helps ensure that a diverse pool of highly trained scientists is available in appropriate scientific disciplines to meet the nation’s biomedical, behavioral, and clinical research needs.

[NRSA for Individual Predoctoral MD/PhD Degree Fellows \(F30\)](#)


[NRSA for Individual Predoctoral Fellows \(F31\)](#)

[NRSA for Individual Postdoctoral Fellows \(F32\)](#)

[NRSA Institutional Research Training Grant \(T32\)](#)

National Research Service Awards (NRSAs) Predoctoral and Postdoctoral Trainees (Full-Time Trainee Positions)

Fiscal Years 2014 - 2024




cancer.gov

Research Career Awards “K” Program

The NCI career development (K) awards program includes a broad range of funding mechanisms and provides scientists with support to further develop their cancer research careers, transition to independence, expand their existing research programs, or mentor junior investigators. The K awards are a significant component of NCI’s training effort.


Total Number of K Awards

Fiscal Years 2014 - 2024



Percent of Total Research Career Awards Funded

Fiscal Year 2024



- K00 Post-Doc-Fellow Awards
- K01 Research Scientist Development Award
- K05 Research Scientist Award
- K07 Preventive Oncology
- K08 Clinical Investigator
- K12 Institutional Clinical Oncology Research
- K22 Transitional Career Development
- K23 Patient-Oriented Career
- K24 Patient-Oriented Career - Mid Career
- K25 Mentored Quantitative Research Career Development Award
- K43 Mentored Career Devel/Temin Intl Career
- K99 NIH Pathway to Independence Awards

cancer.gov

Grant and Contract Awards

This page displays the number and dollar amount of grant and contract awards by state and country, with details for institutions receiving more than \$15 million in support from NCI.

Grants are used when no substantial programmatic involvement is anticipated between NCI and the grant recipient during performance of the financially assisted activities. They are also used when there is no expectation on the part of NCI of a specified service or product for NCI.


Contracts are used to procure cancer research services and other resources that the federal government needs to advance the NCI cancer research mission.

Moving forward, all NCI obligations related to grants and contract awards will be included for each fiscal year. According to the National Institutes of Health's Office of Extramural Research, the "Count Rules" and associated policy guidelines are updated annually, with funding limits determined by cost center and division. A value of "0" indicates an award that is funded by another NIH Institute but is co-funded by the NCI.

Grant and Contract Awards by State and Institution

In the map graphic below, grant and contract awards are presented by state. The table below the graphic provides information for U.S. territories. Within each state on the graphic, hover to view the total amount awarded and click to view detailed data on institutions that received more than \$15 million in support from NCI during fiscal year 2024. For purposes of the NCI Budget Fact Book, institutions include universities, cancer centers, and hospitals.

Grant and Contract Awards by State and Institution, FY 2024



GRANT AWARDS BY STATE, FY 2024

(Whole Dollars)

State	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Alabama	80	\$38,267,179	0	\$0	80	\$38,267,179
Alaska	2	\$1,194,564	0	\$0	2	\$1,194,564
Arizona	62	\$36,186,273	0	\$0	62	\$36,186,273
Arkansas	21	\$7,027,667	0	\$0	21	\$7,027,667
California	978	\$614,150,097	0	\$0	978	\$614,150,097

(Continued from previous page)

State	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Colorado	94	\$42,965,447	0	\$0	94	\$42,965,447
Connecticut	137	\$63,725,309	0	\$0	137	\$63,725,309
Delaware	9	\$5,082,317	0	\$0	9	\$5,082,317
Dist Of Col	69	\$36,537,335	0	\$0	69	\$36,537,335
Florida	222	\$111,933,853	0	\$0	222	\$111,933,853
Georgia	135	\$68,540,930	0	\$0	135	\$68,540,930
Hawaii	20	\$18,118,336	0	\$0	20	\$18,118,336
Idaho	1	\$424,500	0	\$0	1	\$424,500
Illinois	259	\$148,845,532	0	\$0	259	\$148,845,532
Indiana	81	\$41,983,040	0	\$0	81	\$41,983,040
Iowa	31	\$16,474,412	0	\$0	31	\$16,474,412
Kansas	28	\$13,867,899	0	\$0	28	\$13,867,899
Kentucky	49	\$21,556,044	0	\$0	49	\$21,556,044
Louisiana	28	\$13,968,695	0	\$0	28	\$13,968,695
Maine	15	\$9,536,624	0	\$0	15	\$9,536,624
Maryland	218	\$114,173,711	0	\$0	218	\$114,173,711
Massachusetts	661	\$384,428,561	0	\$0	661	\$384,428,561
Michigan	220	\$111,646,183	0	\$0	220	\$111,646,183
Minnesota	181	\$115,286,954	0	\$0	181	\$115,286,954
Mississippi	2	\$603,338	0	\$0	2	\$603,338
Missouri	173	\$91,631,809	0	\$0	173	\$91,631,809

(Continued from previous page)

State	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Montana	4	\$2,153,715	0	\$0	4	\$2,153,715
Nebraska	42	\$17,323,908	0	\$0	42	\$17,323,908
Nevada	4	\$2,285,893	0	\$0	4	\$2,285,893
New Hampshire	34	\$18,538,972	0	\$0	34	\$18,538,972
New Jersey	80	\$40,963,723	0	\$0	80	\$40,963,723
New Mexico	16	\$9,941,462	0	\$0	16	\$9,941,462
New York	936	\$534,116,973	0	\$0	936	\$534,116,973
North Carolina	308	\$152,375,497	0	\$0	308	\$152,375,497
Ohio	273	\$146,258,353	0	\$0	273	\$146,258,353
Oklahoma	31	\$16,216,171	0	\$0	31	\$16,216,171
Oregon	84	\$55,634,371	0	\$0	84	\$55,634,371
Pennsylvania	459	\$300,932,229	0	\$0	459	\$300,932,229
Rhode Island	19	\$6,491,464	0	\$0	19	\$6,491,464
South Carolina	68	\$35,541,934	0	\$0	68	\$35,541,934
South Dakota	3	\$1,531,804	0	\$0	3	\$1,531,804
Tennessee	189	\$116,601,953	0	\$0	189	\$116,601,953
Texas	664	\$338,841,966	0	\$0	664	\$338,841,966
Utah	79	\$37,343,518	0	\$0	79	\$37,343,518
Vermont	13	\$7,959,644	0	\$0	13	\$7,959,644
Virginia	124	\$78,221,223	0	\$0	124	\$78,221,223

(Continued from previous page)

State	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Washington	229	\$163,050,492	0	\$0	229	\$163,050,492
West Virginia	7	\$2,252,337	0	\$0	7	\$2,252,337
Wisconsin	116	\$77,933,851	0	\$0	116	\$77,933,851
Subtotal	7,558	\$4,290,668,062	0	\$0	7,558	\$4,290,668,062
Guam	1	\$1,318,336	0	\$0	1	\$1,318,336
Puerto Rico	8	\$4,372,748	0	\$0	8	\$4,372,748
Total	7,567	\$4,296,359,146	0	\$0	7,567	\$4,296,359,146

Grant and Contract Awards by Country

NCI funds and co-funds cancer research all over the world. The table below lists number and dollar amount of grant and contract awards by country.

GRANT AND CONTRACT AWARDS BY COUNTRY, FISCAL YEAR 2024

(Whole Dollars)

Country	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Australia	4	\$2,681,681	0	\$0	4	\$2,681,681
Belgium	1	\$131,854	0	\$0	1	\$131,854
Canada	12	\$6,604,118	0	\$0	12	\$6,604,118
Ethiopia	0	\$250,000	0	\$0	0	\$250,000
France	7	\$3,583,009	0	\$0	7	\$3,583,009
Germany	5	\$2,041,735	0	\$0	5	\$2,041,735
Ghana	1	\$234,901	0	\$0	1	\$234,901
Israel	2	\$317,969	0	\$0	2	\$317,969

(Continued from previous page)

Country	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Italy	1	\$134,258	0	\$0	1	\$134,258
Jamaica	0	\$50,000	0	\$0	0	50,000
Kenya	1	\$333,259	0	\$0	1	\$333,259
Netherlands	2	\$254,375	0	\$0	2	\$254,375
Nigeria	0	\$235,184	0	\$0	0	\$235,184
Norway	1	\$74,043	0	\$0	1	\$74,043
Rwanda	1	\$475,730	0	\$0	1	\$475,730
South Africa	5	\$753,703	0	\$0	5	\$753,703
Spain	1	\$102,979	0	\$0	1	\$102,979
Switzerland	1	\$865,228	0	\$0	1	\$865,228
Thailand	0	\$70,000	0	\$0	0	\$70,000
Uganda	1	\$305,169	0	\$0	1	\$305,169
United Kingdom	22	\$5,320,242	0	\$0	22	\$5,320,242
Total	68	\$24,819,437	0	\$0	68	\$24,819,437

NCI Historical Trends

Established in 1937, the National Cancer Institute (NCI) was among the first Institutes of the National Institutes of Health (NIH). From the outset, NCI served as a scientific cornerstone of the NIH. The following links provide information about the history of NCI appropriations and the Professional Judgment (Bypass) Budget, as well as data on funding trends and staffing levels.


NCI Professional Judgment Budget, President's Budget and Appropriations

Professional Judgment Budget, President's Budget, and Enacted Appropriations Comparison

This graph displays a historical view of the Professional Judgment Budget, the President's Budget, and the Enacted Appropriations for the NCI from fiscal years 1974 through 2026. The National Cancer Act gives the NCI Director special authority to submit an annual Professional Judgment Budget, sometimes referred to as the "Bypass Budget," directly to the President and Congress. This budget reflects NCI cancer research priorities and identifies areas of potential investment in cancer research. The President's Budget is an annual report prepared by the White House, in coordination with federal agencies. It proposes funding levels for the federal government, including for the NIH and NCI, according to the President's priorities. Congress reviews the Professional Judgment Budget and the President's Budget, and then conducts its own inquiries and hearings to develop and pass an appropriations bill to fund the government. When the bill is signed into law by the President, the Enacted Appropriation levels become available for NCI's cancer research activities.

Professional Judgment Budget, President's Budget, and Enacted Appropriation Comparison

Fiscal Years 1974 - 2025



FY	Professional Judgement Budget*	President's Budget*	Enacted Appropriation*
1974	\$640,031	\$500,000	\$551,192
1975	\$750,000	\$600,000	\$691,666
1976	\$898,500	\$605,000	\$914,628
1977	\$948,000	\$687,670	\$815,000
1978	\$955,000	\$818,936	\$872,388
1979	\$1,036,000	\$878,802	\$937,129
1980	\$1,055,000	\$936,958	\$1,000,000
1981	\$1,170,000	\$1,007,800	\$989,355
1982	\$1,192,000	\$1,025,946	\$986,617

(Continued from previous page)

FY	Professional Judgement Budget*	President's Budget*	Enacted Appropriation*
1983	\$1,197,000	\$955,449	\$987,642
1984	\$1,074,000	\$986,681	\$1,081,581
1985	\$1,189,000	\$916,485	\$1,183,806
1986	\$1,460,000	\$1,126,012	\$1,264,159
1987	\$1,570,000	\$1,158,089	\$1,402,837
1988	\$1,700,000	\$1,302,823	\$1,469,327
1989	\$2,080,000	\$1,468,256	\$1,593,536
1990	\$2,195,000	\$1,494,741	\$1,664,000
1991	\$2,410,000	\$1,694,059	\$1,766,324
1992	\$2,612,000	\$1,810,230	\$1,989,278
1993	\$2,775,000	\$2,010,439	\$2,007,483
1994	\$3,200,000	\$2,142,122	\$2,082,267
1995	\$3,600,000	\$1,967,709	\$2,135,119
1996	\$3,640,000	\$1,994,007	\$2,251,084
1997	\$2,977,000	\$2,060,392	\$2,382,532
1998	\$2,702,500	\$2,217,482	\$2,547,314
1999	\$3,191,000	\$2,528,760	\$2,927,187
2000	\$3,873,000	\$2,732,795	\$3,332,317
2001	\$4,135,000	\$3,249,730	\$3,757,242

(Continued from previous page)

FY	Professional Judgement Budget*	President's Budget*	Enacted Appropriation*
2002	\$5,030,000	\$4,177,203	\$4,190,405
2003	\$5,690,000	\$4,673,510	\$4,622,394
2004	\$5,986,000	\$4,770,519	\$4,770,519
2005	\$6,211,000	\$4,870,025	\$4,865,525
2006	\$6,170,000	\$4,841,774	\$4,841,774
2007	\$5,949,714	\$4,753,609	\$4,797,639
2008	\$5,865,788	\$4,782,114	\$4,890,525
2009	\$6,028,386	\$4,809,819	\$4,968,973
2010	\$7,193,393	\$5,150,170	\$5,103,388
2011	\$6,199,666	\$5,264,643	\$5,103,388
2012	\$5,869,857	\$5,196,136	\$5,081,788
2013	\$5,833,010	\$5,068,864	\$5,072,183
2014		\$5,125,951	\$4,923,238
2015		\$4,930,715	\$4,950,396
2016	\$5,754,000	\$5,098,479	\$5,214,701
2017	\$5,453,000	\$5,893,509	\$5,689,329
2018		\$4,474,222	\$5,964,800
2019	\$6,380,000	\$5,626,312	\$6,143,892
2020	\$6,522,000	\$5,246,737	\$6,440,442

(Continued from previous page)

FY	Professional Judgement Budget*	President's Budget*	Enacted Appropriation*
2021	\$6,928,000	\$5,881,173	\$6,559,852
2022	\$7,609,000	\$6,733,302	\$6,912,522
2023	\$7,766,000	\$6,713,851	\$7,320,159
2024	\$9,988,000	\$7,820,159	\$7,224,159
2025	\$11,466,000	\$7,839,141	\$7,224,159
2026	\$11,466,000		

* Dollars in thousands

- The Professional Judgment Budget was not released in FY 2014, FY 2015, or in FY 2018. To learn more about this authority and view the budget archive, please visit NCI's [About the Annual Plan](#) and [Budget Proposal page](#).
- The FY 2017 and FY 2018 Enacted Appropriated budget includes \$300,000,000 of Cancer MoonshotSM funding. \$400,000,000, \$195,000,000, and \$195,000,000 of Cancer MoonshotSM funding are included in the FY 2019, FY 2020, and FY 2021 Enacted Appropriated levels, respectively. The Professional Judgment Budget also includes \$400,000,000, \$195,000,000, \$195,000,000, \$194,000,000 and \$216,000,000 of Cancer Moonshot funding in fiscal years 2019, 2020, 2021, 2022, and 2023, respectively. The FY 2024 President's Budget includes Moonshot funding as a part of NCI's base appropriation. The FY 2025 President's Budget includes discretionary Moonshot funding as a part of NCI's base appropriation, but excludes mandatory Moonshot funding.
- The Enacted Appropriation levels do not include potential adjustments such as Rescissions, Sequestrations, Supplemental funding, or Secretary's Transfers that may have impacted the amount available for NCI expenditure.

NCI Appropriations

The NCI budget for FY 2024 (October 1, 2023 through September 30, 2024) is \$7.22 billion. During the period from 2010 through 2024, the NCI budget averaged \$5.84 billion per year.

APPROPRIATIONS OF THE NCI, 1938–2023

(Whole Dollars)

Fiscal Years	Amount	Notes
1938–2002	\$52,940,982,220	
2003	\$4,622,394,000	Prior to reductions in PL 108-7(-\$30,046,000 for the enacted rescission and \$2,000 lapse). Includes \$263,442,000 of AIDS funding.
2004	\$4,770,519,000	Prior to reductions in PL 108-199(-\$3,136,000 for Labor/HHS/ED rescission; \$28,128,000 for across the board reduction; -\$15,357,000 NIH 1% transfer assessment, and \$5,000 lapse). Includes \$266,975,000 of AIDS funding.
2005	\$4,865,525,000	Prior to reductions in PL 108-447(\$38,914,000 .8% across the board reduction; -\$1,353,000 for Labor/HHS/ED rescission; -\$30,505,000 NIH 1% transfer assessment, and \$9,000 lapse). Includes \$265,907,000 of AIDS funding.
2006	\$4,841,774,000	Prior to reductions in PL 109-149 (-\$48,418,000 for Labor/HHS/ED rescission; -\$3,293,000 HHS transfer for CMS activities; -\$42,834,000 NIH 1% transfer for roadmap activities, and \$4,000 lapse). Includes \$253,666,000 of AIDS funding.
2007	\$4,797,639,000	Prior to reductions in PL 110-5 (-\$5,015,000 NIH transfer for GEI activities, and \$9,000 lapse). Includes \$253,666,000 of AIDS funding.
2008	\$4,890,525,000	Prior to -\$85,437,000 rescission and \$3,091,000 in NIH transfer activities. Includes supplemental appropriation of \$25,559,000. Includes \$258,499,000 of AIDS funding.
2009	\$4,968,973,000	Prior to reductions in PL 111-8 (-\$2,042,631 NIH transfer for activities, and \$4,000 lapse). Includes \$265,882,000 of AIDS funding.

(Continued from previous page)

Fiscal Years	Amount	Notes
2010	\$5,103,388,000	Prior to -\$760,000 HHS Secretary's transfer, -\$4,459,000 in NIH transfer for activities, and \$22,000 lapse. Includes \$272,130,000 of AIDS funding.
2011	\$5,103,388,000	Prior to -\$44,810,787 rescission and \$472,000 lapse. Includes \$269,953,000 of AIDS funding.
2012	\$5,081,788,000	Prior to \$9,605,579 rescission, -\$1,445,000 HHS Secretary's transfer, -\$3,342,000 HHS Secretary's transfer for Alzheimer's research, and \$54,000 lapse. Includes \$271,692,000 of AIDS funding.
2013	\$5,072,183,000	Prior to -\$254,589,000 under sequestration (Budget Control Act, 2011, PL 112-25), -\$10,144,367 rescission, -\$28,044,000 HHS Secretary's transfer and +\$9,714,000 restored from the National Children's Study and National Eye Institute HIV/AIDS funding, and \$106,000 lapse. Includes \$261,550,000 of AIDS funding.
2014	\$4,923,238,000	Prior to -\$12,359,000 HHS Secretary's transfer, -\$965,000 HHS Secretary's Cybersecurity Transfer (authorized by section 206 of P.L. 113-76), +\$16,180,552 transfer from National Children's Study, and +\$6,307,000 transfer from NIH Office of AIDS Research, and \$33,000 lapse. Includes \$269,212,000 of AIDS funding.
2015	\$4,950,396,000	Prior to +\$2,632,000 transfer from NIH Office of AIDS Research and \$435,000 lapse. Includes \$269,660,000 of AIDS funding.
2016	\$5,214,701,000	Prior to -\$7,217,390 HHS Secretary's transfer, -\$1,192,000 transfer to NIH Office of AIDS Research, and \$122,000 lapse. Includes \$266,422,000 of AIDS funding.
2017	\$5,689,329,000	Prior to -\$11,971,000 HHS Secretary's transfer, -\$17,403,000 transfer to NIH Office of AIDS Research, and \$247,000 lapse. Includes \$249,019,000 of AIDS funding and \$300,000,000 of Cancer Moonshot SM funding.

(Continued from previous page)

Fiscal Years	Amount	Notes
2018	\$5,964,800,000	Prior to -\$13,309,000 HHS Secretary's transfer, -\$7,785,000 transfer to NIH Office of AIDS Research, and \$250,000 lapse. Includes \$241,234,000 of AIDS funding and \$300,000,000 of Cancer Moonshot SM funding.
2019	\$6,143,892,000	Prior to -\$19,730,000 HHS Secretary's transfer, -\$2,874,000 transfer to NIH Office of AIDS Research, and \$252,786 lapse. Includes \$241,979,000 of AIDS funding and \$400,000,000 of Cancer Moonshot SM funding.
2020	\$6,440,442,000	Prior to -\$4,000 transfer to NIH Office of AIDS Research, and \$254,618 lapse. Includes \$241,975,000 of AIDS funding and \$195,000,000 of Cancer Moonshot SM funding.
2021	\$6,559,852,000	Prior to -\$1,047,000 transfer to NIH Office of AIDS Research, Secretary's Transfer -\$19,109,000, and \$289,223 lapse. Includes \$240,513,000 of AIDS funding, and \$195,000,000 of Cancer Moonshot SM funding.
2022	\$6,912,522,000	Prior to -\$2,896,000 transfer to NIH Office of AIDS Research and \$248,297 lapse. Includes \$248,940,000 of AIDS funding, and \$194,000,000 of Cancer Moonshot SM funding.
2023	\$7,320,159,000	Prior to -\$2,918,000 transfer to NIH Office of AIDS Research, and \$234,418 lapse. Includes \$256,734,000 of AIDS funding, and \$216,000,000 of Cancer Moonshot SM funding.
2024	\$7,224,159,000	Prior to -\$2,918,000 transfer to NIH Office of AIDS Research, and \$324,597 lapse. Includes \$256,734,000 of AIDS funding.
1938 - 2024	\$174,402,568,220	

NCI Funding Trends

Funding amounts and percentages reflect actual obligations for each fiscal year.

NCI Funding

FUNDING BY MECHANISM, FY 2018–2024

(Dollars in Millions)

Mechanism	2018**	2019**	2020**	2021**	2022**	2023**	2024**
Total NCI	\$5,927.6	\$5,992.3	\$6,383.3	\$6,442.7	\$6,833.6	\$7,186.8	\$7,220.9
Research Project Grants	2,450.6	2,541.7	2,749.4	2,822.4	2,966.5	3,145.2	3,129.8
Cancer Centers	331.4	337.1	382.0	344.7	339.7	353.5	352.3
SPOREs	115.8	110.7	113.2	119.6	128.2	124.1	111.2
Other P50s/P20s	0.0	7.4	7.9	3.3	13.2	5.3	5.1
Specialized Centers	178.3	200.8	110.7	95.9	105.9	141.5	137.6
Clinical Cooperative Groups	255.3	290.1	295.6	300.0	307.9	303.6	302.9
R&D Contracts	825.4	768.1	823.0	812.2	835.8	899.1	888.2
Intramural Research	945.5	964.9	1,072.6	1,102.5	1,230.4	1,278.5	1,345.4
Other Mechanisms*	825.3	771.5	829.0	842.0	906.1	936.0	948.4

*The "Other Mechanisms" category includes the Career Program, Cancer Education, Minority Biomedical Research Support, Other Research Grants, National Research Service Awards (NRSA), Research Management & Support, and Buildings & Facilities.

**Fiscal years 2017 through 2024 includes Cancer MoonshotSM funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2022.

Percent Change by Mechanism

PERCENT CHANGE BY MECHANISM, FY 2018–2024

Mechanism	2017 to 2018	2018 to 2019	2019 to 2020	2020 to 2021	2021 to 2022	2022 to 2023	2023 to 2024
Total NCI	5.2%	1.1%	6.5%	0.9%	6.1%	5.2%	0.5%
Research Project Grants	7.6%	3.7%	8.2%	2.7%	5.1%	6.0%	-0.5%
Cancer Centers	5.9%	1.7%	13.3%	-9.8%	-1.5%	4.1%	40.1%
SPOREs	3.9%	-4.4%	2.3%	5.6%	7.2%	-3.2%	-8.9%
Other P50s/P20s	-100.0%	0.0%	6.5%	-58.4%	299.4%	-59.9%	-3.8%
Specialized Centers	31.5%	12.6%	-44.9%	-13.3%	10.4%	33.6%	-2.8%
Clinical Cooperative Groups	4.1%	13.6%	1.9%	1.5%	2.6%	-1.4%	-0.2%
R&D Contracts	-6.2%	-6.9%	7.1%	-1.3%	2.9%	7.6	-1.2%
Intramural Research	5.1%	2.1%	11.2%	2.8%	11.6%	3.9	-13.6%
Other Mechanisms*	7.0%	-6.5%	7.5%	1.6%	7.6%	3.3%	0.0%

*The "Other Mechanisms" category includes the Career Program, Cancer Education, Minority Biomedical Research Support, Other Research Grants, National Research Service Awards (NRSA), Research Management & Support, and Buildings & Facilities.

**Fiscal years 2017 through 2024 includes Cancer MoonshotSM funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2022.

Percent Share of Total NCI Dollars

MECHANISM SHARE OF NCI BUDGET, FY 2018–2024


Mechanism	2018	2019	2020	2021	2022	2023	2024
Research Project Grants	41.3%	42.4%	43.1%	43.8%	46.0%	46.0%	45.8%
Cancer Centers	5.6%	5.6%	6.0%	5.4%	5.3%	5.2%	7.2%
SPOREs	2.0%	1.8%	1.8%	1.9%	2.0%	1.8%	1.7%
Other P50s/ P20s	0.0%	0.1%	0.1%	0.1%	0.2%	0.1%	0.1%
Specialized Centers	3.0%	3.4%	1.7%	1.5%	1.6%	2.1%	2.0%
Clinical Cooperative Groups	4.3%	4.8%	4.6%	4.7%	4.8%	4.4%	4.4%
R&D Contracts	13.9%	12.8%	12.9%	12.6%	13.0%	13.2%	13.0%
Intramural Research	16.0%	16.1%	16.8%	17.1%	19.1%	18.7%	16.2%
Other Mechanisms*	13.9%	12.9%	13.0%	13.1%	14.1%	13.7%	13.7%

*The "Other Mechanisms" category includes the Career Program, Cancer Education, Minority Biomedical Research Support, Other Research Grants, National Research Service Awards (NRSA), Research Management & Support, and Buildings & Facilities.

**Fiscal years 2018 through 2024 includes Cancer MoonshotSM funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2018 through 2022.

Extramural vs Intramural and RMS Funding

The following is a comparison broken out by mechanism and total between Extramural dollars spent vs Intramural Research Program (IRP) and Research Management and Support (RMS).



*Fiscal years 2023 through 2017 includes Cancer MoonshotSM funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2023 through 2018.

FY 2017-2024 TOTAL NCI FUNDING

(Dollars in Millions)

2017*	2018*	2019*	2020*	2021*	2022*	2023*	2024	2017-2024 % Change
\$5,636.4	\$5,927.7	\$5,992.3	\$6,383.4	\$6,442.7	\$6,833.7	\$7,186.8	\$7,240.9	0.8%

*Fiscal years 2017 through 2023 include Cancer MoonshotSM funding appropriated that fiscal year and exclude all carryover obligations for fiscal years 2018 through 2023.

FY 2017–2024 EXTRAMURAL FUNDING

(Dollars in Millions)

Mechanism	2017*	2018*	2019*	2020*	2021*	2022*	2023*	2024	2017-2024 % Change
Research Project Grants	\$2,278.4	\$2,450.6	\$2,541.7	\$2,749.4	\$2,822.4	\$2,966.5	\$3,145.2	\$3,129.8	-0.5%
Cancer Centers	313.0	331.4	337.1	382.0	344.7	339.7	353.5	495.1	40.1%
SPOREs	111.4	115.8	110.7	113.2	119.6	128.2	124.1	113.9	-8.2%
Other P50s/P20s	1.3	0.0	7.4	7.9	3.3	13.2	5.3	5.3	0.0%
Other Specialized Centers	135.6	178.3	200.8	110.7	95.9	106.0	141.5	137.6	-2.8%
Other Research Grants	481.9	537.9	506.8	548.1	556.2	624.8	621.5	606.4	-2.4%
NRSA	77.6	82.4	87.0	96.4	93.0	91.1	90.3	89.9	-0.4%
R&D Contracts	880.4	825.4	768.1	823.0	812.2	835.8	899.1	888.2	-1.2%
Buildings & Facilities	30.0	18.0	18.0	30.0	30.0	30.0	30.0	30.0	0.0%
Total Extramural Funds	\$4,309.7	\$4,539.8	\$4,577.5	\$4,860.7	\$4,877.3	\$5,135.3	\$5,410.5	\$5,496.2	1.6%

*Fiscal years 2017 through 2023 include Cancer MoonshotSM funding appropriated that fiscal year and exclude all carryover obligations for fiscal years 2018 through 2023.

FY 2017–2024 INTRAMURAL AND RMS FUNDING

(Dollars in Millions)

Mechanism	2017*	2018*	2019*	2020*	2021*	2022*	2023*	2024	2017-2024 % Change
Intramural Research	\$899.7	\$945.5	\$964.9	\$1,072.6	\$1,102.5	\$1,230.4	\$1,278.5	\$1,345.4	5.2%
RMS	427.0	442.4	449.9	450.0	462.9	468.0	497.8	399.3	-19.8%
Total IRP & RMS Funds	\$1,326.7	\$1,387.9	\$1,414.8	\$1,522.6	\$1,565.4	\$1,698.4	\$1,776.3	\$1,744.7	-1.8%


*Fiscal years 2017 through 2023 include Cancer MoonshotSM funding appropriated that fiscal year and exclude all carryover obligations for fiscal years 2018 through 2023.

Comparison of Dollars, Positions, and Space

This page presents tables comparing NCI's budget, full-time equivalent (FTE) positions, and occupied space spanning fiscal years 2015 through 2024.

NCI's budget is displayed in millions of dollars and includes the Cancer MoonshotSM funding in fiscal years 2017 through 2023. FTEs are the number of work years for appointed employees of NCI. A work year equals 2,080 hours. Space is in thousands of square feet, excluding NCI's Frederick National Laboratory for Cancer Research.

In fiscal year 2020, NCI acquired new laboratory space (called the Consolidated Research Lab) in Shady Grove and new administrative space in Bethesda.



NCI Personnel

The table below displays NCI staffing levels by type of appointment for fiscal years 2010 through 2024.

- full-time equivalents represent 2,080 hours per person employed
- full-time and part-time appointments include employees from NIH Employment Report 71E
- training Fellows including visiting fellows, Cancer Research Training Award (CRTA) and the few remaining Intramural Research Training Award (IRTA), biotech, and tech transfers
- total employees include full-time and part-time permanent tours


NCI PERSONNEL, FY 2010–2024

Fiscal Year	Full Time Permanent	Other Than Full Time Permanent	Training Fellows	Total Personnel Resources
2010	2,148	1,011	1,073	4,232
2011	2,180	1,029	1,108	4,317
2012	2,139	997	906	4,042
2013	2,173	948	847	3,968
2014	2,139	923	879	3,941
2015	2,119	897	947	3,963
2016	2,050	1,001	972	4,023
2017	2,156	890	1,042	4,088
2018	2,083	845	1,045	3,973
2019	2,101	879	1,061	4,041
2020	2,136	952	1,150	4,143
2021	2,188	1,007	1,133	4,328
2022	2,187	1,047	1,153	4,387
2023	2,266	1,050	1,186	4,502
2024	2,263	1,085	1,084	4,432

NCI and NIH AIDS Funding History

NCI has played a major role in HIV/AIDS research since the beginning of the AIDS epidemic. Scientists within NCI, as well as those supported by NCI, have made a number of key discoveries. HIV/AIDS research is conducted throughout the divisions and offices of NCI and is coordinated by the [NCI Office of HIV and AIDS Malignancy](#).

In addition, because HIV/AIDS transcends every area of clinical medicine and basic scientific investigation, the NIH AIDS research effort involves every NIH Institute and Center. The NIH Office of AIDS Research has primary responsibility for planning and coordinating AIDS research across NIH.



Cancer MoonshotSM – Recent Fiscal Year Funding

The 21st Century Cures Act, which was signed into law in December 2016, authorized \$1.8 billion to fund the Cancer Moonshot over a 7 year period. The goal of the Cancer Moonshot is to accelerate progress in cancer, including prevention and screening, from cutting edge basic research to wider uptake of standard of care.

More information on Cancer Moonshot can be found by visiting the [NCI Cancer Moonshot initiative page](#).

Information on recent funding opportunity announcements can be found on the [Cancer Moonshot Funding Opportunities page](#).

CANCER MOONSHOT FISCAL YEAR SUMMARY

(Whole Dollars)


Fiscal Year	Authorization
2017	\$300,000,000
2018	\$300,000,000
2019	\$400,000,000
2020	\$195,000,000
2021	\$195,000,000
2022	\$194,000,000
2023	\$216,000,000
Total	\$1,800,000,000

Cancer MoonshotSM – Obligations by Budget Mechanism

With over \$117 million carryover funds for Cancer Moonshot activities in fiscal year (FY) 2024, funding was allocated into four budget mechanisms: research grants, R&D contracts, intramural research, and research management and support, as shown in the chart below.

FY 2024 Cancer Moonshot and Carryover – Obligations by Mechanism

Fiscal Year 2024



cancer.gov

FY 2024 CANCER MOONSHOTSM CARRYOVER – OBLIGATIONS BY MECHANISM

(Whole Dollars)

Type of Mechanism	Mechanism	Number	Amount ¹
Research Project Grants (RPGs)	Competing	21	\$16,985,816
	Noncompeting	32	\$21,070,638
	Admin Supplements	0	\$2,653,674
	Subtotal, without SBIR	0	\$0
	SBIR/STTR Grants	0	\$0
	Subtotal, RPGs	53	\$40,710,128
Centers	Cancer Centers-P30s	0	\$721,495
	P50s	2	\$862,041
	Cooperative Agreements-U54s/U41s	1	\$267,596
	Subtotal, Centers	3	\$1,851,132
Other Research	Resource Grants-U24s/U2Cs		\$25,665,318
	Subtotal, Other Research		\$25,665,318
Subtotal, Research Grants			\$68,226,578

Type of Mechanism	Mechanism	Number	Amount ¹
Intramural Research	IR Program	0	\$4,960,447
Research Management & Support	RMS	0	\$141,095
R&D Contracts	R&D Contracts		\$44,532,683
	SBIR/STTR Contracts		\$0
	Subtotal, R&D Contracts		\$44,532,683
Total			\$117,860,803

¹ Includes obligations and recoveries from fiscal years 2017, 2018, 2019, 2020, 2021, 2022, and 2023 carryover accounts.

Cancer MoonshotSM – Funding by Research Category

To ensure the Cancer Moonshot goals and approaches were grounded in the best science, NCI convened a [Blue Ribbon Panel of scientific experts](#) as a working group to the National Cancer Advisory Board. In September of 2016, the Blue Ribbon Panel presented a [final report](#) outlining 10 research recommendations representing areas that are well-positioned to accelerate progress in cancer prevention, diagnosis, treatment, and care.

The following research categories align with these 10 recommendations:

Research Category	Amount ¹
Network for Direct Patient Engagement	\$14,637,947
Cancer Immunotherapy Translational Science Network	\$8,837,639
Therapeutic Target Identification to Overcome Drug Resistance	\$2,228,942
A National Cancer Data Ecosystem for Sharing and Analysis	\$21,434,446
Fusion Oncoproteins in Childhood Cancers	\$282,910
Minimize Cancer Treatment’s Debilitating Side Effects	\$3,679,370
Prevention and Early Detection: Implementation of Evidence-Based Approaches	\$11,907,567
Retrospective Analysis of Biospecimens from Patients Treated with Standard of Care	\$0
Generation of Human Tumor Atlases	\$12,881,852
Development of New Enabling Cancer Technologies	\$17,277,841
Other Cancer Moonshot Priority Activities (e.g., Partnership for Accelerating Cancer Therapies)	\$24,692,289
Total	\$117,860,803

¹ Includes new obligations and recoveries from fiscal years 2017, 2018, 2019, 2020, 2021, 2022, and 2023 carryover accounts.



**NATIONAL
CANCER
INSTITUTE**

[cancer.gov](https://www.cancer.gov)